About us
Our Mission
We exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with our four-in-one biologic drug, AUP-16.
Our Vision
Our goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.
Leadership Team
JUHA YRJÄNHEIKKI
CEO
LAURENT DÉCORY
COO
THOMAS WIRTH
CSO
HARITHA SAMARANAYAKE
CMO
MAIJA RUSI
Financial & Administrative Director
IGOR MIERAU
Director of CMC
SCIENTIFIC ADVISORY BOARD
BOARD OF DIRECTORS
